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     Nucleostemin (NS), a stem cell-abundant nucleolar protein, is critical for maintaining the self-renewal 
and proliferative properties of normal and cancerous stem cells. Recent data suggests that NS signaling is 
important for proliferation of T-cells and leukemia cells. This study was conducted to verify the role of NS 
in pathogenesis and treatment of T-cell acute lymphocytic leukemia (T-ALL). Our results revealed that RNA 
interference-mediated NS silencing primarily affected clonogenicproperty of T-ALL cells by limiting their 
self-renewal potential in vitro.These effects were accompanied with inhibition of proliferation and early 
apoptosis in Jurkat cells (p53-null) while late apoptosis in Molt-4 (p53 functional) T-ALL cells. 
Collectively, our results suggest that NS is a critical regulator in self-renewal and apoptosis of differentT-
ALL cells. This suggests therapeutic potential of this gene in leukemia. 
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INTRODUCTION 
     T-cell acute lymphoblastic leukemia (T-ALL) 
is an aggressive type of leukemia, accounting for 
10–15% pediatric and 25% of adult ALL cases 
[1,2]. The disease is caused by an accumulation 
of abnormal immature T lymphoblasts as result 
of multistep genetic alterations in leukemia 
initiating cells, so-called leukemia stem cells 
(LSCs) [1,3]. Like other types of leukemia, T-
ALL LSCs are characterized by indefinite self-
renewal, uncontrolled cell cycle progression, 
impaired differentiation and loss of sensitivity to 
apoptosis [2,3]. Although, the treatment outcome 
in T-ALL has been tremendously improved with 
the current therapeutic protocols,the average 
overall survival of the patients with resistance 
and relapse remains poor[3,4].Due to this 
relative lack of efficacy, identifying more 
effective targets and strategies is essential for 
treat of this type of leukemia. 
Signaling circuitscontrolling stem cell self-
renewal areabruptly down-regulatedduring 
differentiation prior to terminal cell divisionbut 
often reactivated during malignant 
transformation [5]. To date, the intricate 
molecular machinery and the signaling 
mechanisms regulating fate of T-ALL is not 
clear.In particular, the role of NS developmental 
signaling pathways in the pathogenesis of T-
ALL remains to be delineatedmore [2].NS is 
reported to be a marker of stem cells that is 
involved in controlling self-renewal, cell-cycle 
progression and proliferation in both stem cells 
and cancerous cells [6]. The expression of 
thisGTP-binding protein is rapidly decreased 
during terminal differentiation of stem cells 
[7,8].  Mechanistically, the effects of NS are 
mediated via p53, although some p53-
independent mechanisms have been reported in 
cancerous cells [9-11]. 
 




Recently, scientists reported that NS gene 
silencing caused cell-cycle arrest and cell death 
of leukemia cell lines such as K562 and Molt-4 
cells, suggesting that this nucleolar protein might 
be an attractive molecular target for developing 
anti-leukemiatherapy [2,12]. We designed this 
study to better study the importance of NS in self-
renewal and apoptosis of T-ALL cells.  
 
MATERIAL AND METHODS 
Cell line and cell culture 
     Molt-4 and Jurkat cell lines were purchased 
from the Pasteur Institute of Iran and were cultured 
in RPMI1640Medium with 10%Foetal Bovine 
Serum (FBS) (Biosera), 100 g/ml Streptomycin, 
100 u/mL Penicillin (Cinagen, Tehran) and was 
maintained at 37°C in a humidified atmosphere 
with 5% CO2. 
siRNA design and synthesis 
    There double stranded, short interfering RNAs 
(siRNA) against all NS mRNA variants were 
designed as previously reported [2]. The sequences 
for NS-siRNA and IR-siRNA were: 5’-
GAACUAAAACAGCAGCAG AdTdT-3' and 5′-
UGA CGA UCA GAA UGC GAC UdTdT-3′, 
respectively. 
Transfection of cells with NS-siRNA 
     For transfection, 2 10
5
 cells/well were cultured 
in 100L of RPMI1640 medium supplemented 
with 10% serum within 24 well plate (SpL Life 
sciences, South Korea). In brief, different 
concentrations of siRNA solutions were mixed 
separately with HiPerFect transfection reagent 
(Qiagen, USA) in 100L serum free medium 
RPMI1640 for each well. After 15 minutes 
incubation at room temperature, the resulting 
mixture was moved to the cell containing well in 
the plate. After 6 hours, 400 l of culture medium 
containing12% serum and antibiotic were added to 
each well.  
Real Time quantitative PCR (q-PCR) 
    Total RNA was extracted from cells with the 
RNX plus kit (Cinagen, Tehran). Equal volume of 
total RNA (1 g) of each sample was treated with 
DNase enzyme andOligodt primer (Fermentase, 
EU). The RNA converted to cDNA using the 
reveres transcription reaction by using the RT 
enzyme (Fermentase, EU). RT-qPCR was 
performed using SYBR Greenby Rotor Gene 6000 
machine (Applied Biosystems)under following 
cycle conditions: 95°C for 10 minutes, followed by 
40 cycles at 57°C for 30 seconds and 72°Cfor 30 
seconds. Results were normalized against ß-actin 
expression. Each QPCR was performed on at least 
three different experimental samples and each 
reaction was performed in triplicate. The forward 
primer and reverse primer of NS were 5`- 
AAAGCCATTCGGGTTGGAGT -3` and 5`- 
ACCACAGCAGTTTGGCAGCAC -3`, 
respectively. Human β2Microglobulin (β2m) gene 
was used as a control for adjusting the relative 
amounts of total RNA between the samples. β2m 
forward and reverse primers were: 5'- 
CTACTCTCTCTTTCTGGCCTG-3' and 5'- 
GACAAGTCTGAATGCTCCAC-3', respectively. 
Growth, viability and Self-renewal assays 
     Trypan blue exclusion test were used to study 
the cell growth and viability. For this purpose, 
10
5
 cells were seeded in each well of 24 well 
plates. After 12, 24, 48, 72 h, the number of viable 
and non-viable cells for each well was counted 
using Trypan blue exclusion test and 
hemocytometer; finally, we drew growth and 
viability curves for each group [2]. For measuring 
self-renewal  capacity of  the cells, Colony 
formation assay was performed in semisolid 
culture medium containing 0.9 % methylcellulose  
and 10 % FBS. In brief, 400 cells were placed into 
1.2% methylcellulose, 30% FBS, 1% bovine serum 
albumin (BSA), 10 µM 2-mercaptoethanol and 2 
mMof L-glutamine. Colonies consisting of >50 
cells were counted using an inverted microscope at 
12-14 days, then harvested and replating in 
methylcellulose [13]. 
Morphological evaluation of the apoptosis  
     Apoptosis was first detected by Fluorescent 
microscopy. In this way control and transfected 
cells were washed in cold PBS and gently mixed 
with a mixture of Acridine orange (AO, 1 μg/ml) 
and ethidium bromide (EtBr,1μg/ml) solution (1 : 
1, v/v). The suspension was put on a microscopic 
slide and viewed under a fluorescent microscopy 
(Nikon E-1000, Japan).  
Statistical analysis 
    Statistical analysis was performed with 
Microsoft Excel 2010 and SPSS14. Independent-
sample t-test was used for comparison. P < 0.05 
 




was considered statistically significant. All 
experiment was replicated at least in triplicate. 
RESULTS 
NS-siRNA efficiently silenced NS in T-ALL cells 
     Theq-PCR results confirmed high expression 
levels of NS in Molt-4 and Jurkatcellsas 
compared with IR-siRNA that was used as a 
control for nonspecific effects of siRNA 
transfection (Figure 1). When we used NS-
siRNA, a significant decrease at the level of NS 
mRNA was observed at 12 h post-transfection 
followed with moreinhibitory effects (more than 
50%) at 24 h and 48 h (Figure 1). For instance, 
the NS gene expression was reduced by about52% 
in Molt-4 cells and 60%in Jurkat cells at 48 h 


























Figure 1. Efficacy of  NS-siRNA in NS depletion in Molt-4 and Jurkat cells. Following transfection of both Molt-4 and Jurkat cells 
with IR- and NS-siRNAs, the mRNA was extracted, and the gene expression level was determined by q-PCR. In comparison with 
IR-siRNA transfected cells,the gene expression level of NS was statistically significant(P<0.05) in all indicated times after 
NS‐siRNA transfection. In all experimentsβ2mwas used as a control for gene expression level. The results were presented as % of 
control gene ± SD.  
 
 
The growth, viability and self-renewal capacity 
of T-ALL cells were inhibited by NS-siRNA 
     To study biological consequence of NS 
depletion, the growth and the viability of Molt-4 
and Jurkatcellswere evaluatedin a time-dependent 
manner. AsshowninFig. 2A, NS-siRNA reduced 
proliferation of bothMolt-4and Jurkat cells by 
26.3±3.7 % and 29.0±2.5 % respectively at 24 
hours post-transfection, respectively. The growth 
inhibitory effects were more prominent at 48hours 
and 72 hours post-transfection(Figurure 2A); by 
40.0±5 and 50.5 ±2.5% in Molt-4 and 44.5±3.0 
and 49.3±2.7% in Jurkat cells, respectively. 
Theviabilityof control and NS-siRNAtransfected 
cellswas also studiedby Trypan blue exclusion 
test (Fig. 2B). In comparison with IR-siRNA, no 
significant decrease in viability of Molt-4 cells 
was observed at 24 h of NS-
siRNAtransfectionwhile the viability was 
significantly reduced (24.5±2.5% %) in Jurkat 
cells at this condition. The viability of both cell 
typeswas significant decreased at 48 hours (by 
22.4±5% for Molt-4 and 35.2±2.5% % for Jurkat) 
and 72 hours (by 46.75±2.5% for Molt-4 and 
Jurkat Molt-4 
 







































Figure 2. Effects of NS-siRNA in growth, viability and self-renewal of Molt-4and Jurkat cells. The growth inhibition (A) and 
viability (B) ofboth cells were determined bytrypan blue exclusion test at 24 h, 48 h and 72 h after transfection with NS-siRNA, as 
mentioned in materials and methods.The results were presented as % of control( IR-siRNA transfected) ± SD. Self-renewal capacity 
was determined by clonogenic recovery of the cells(C and D) following transfection with NS-siRNA.C: After transfection of cells 
with NS-siRNAand plated in duplicate in methylcellulose, the colonies werecounted at 12–14 days (initial plating). D: The primary 
















Figure 3. Effects of NS depletion on apoptosis induction of Molt-4 and Jurkat cells. NS-siRNA transfected cells at 48 h after 
transfection. The cells were stained with AO/EtBr and occurrence of apoptosis was observed by fluorescent microscopy (40×).In 
these figures, viable cells were equally green and early apoptotic cells had bright green blots in their nuclei. Late apoptotic cells, 
however, stained orange and showed condense and fragmented nuclei. Chromatin condensation (short arrows) and apoptotic bodies 









Apoptosis is induced following NS silencing in 
T-ALL cells 
     To know whether apoptosis is ultimate fate of 
T-ALL-depleted cells, we studied condensation a 
fragmentation of nuclear DNA by AO/EtBr 
staining. In this test, viable cells were equally 
green and early apoptotic cells had bright green 
blots in their nuclei. Late apoptotic cells, 
however, stained in orange color and showed 
condense with fragmented nuclei. Based on 
results presented in Fig. 3 an early apoptosis 
(48hours after NS-siRNA transfection), was 
observed in p53− Jurkat cells. In contrast, no 
detectable apoptotic cellswere observed inp53+ 
Molt-4 cells at 48 h of NS depletion (Figure 3).  
However, at longer times of NS depletions (72 
hours and 96 hours) a substantial increase in 




      The problems with current therapeutic 
protocols in T-ALL treatment are drug resistance 
and relapsingof the disease. Indeed, a fraction of 
LSCs with high self-renewal capacity may remain 
after current therapies treatment &that may cause 
relapse and therapeutic failure [4]. To get an exact 
view of the therapeutic potential of NS in 
leukemia, we selected two different models of 
leukemia Molt-4 and Jurkat cells based on p53 
status. By using molecular targeting of one of the 
most important genes, NS, the fate of the cells 
was studied.NSis expressed in many cancer cell 
lines such as gastric cancer, lung cancer, leukemia 
(K562 and HL-60), prostate (PC-3), bladder 
(5637), Crivical (Hela) and mammary tumors 
(MCF-7) and preferentially exist in many stem 
cell- populations [14-19]. Therefore,NS could be a 
potent target therapy in most cancers due to its 
inhibitory effect on the proliferation rate of cells. 
[6]. In this regard, our data not only confirms 
these previous reports on importance of this gene 
in leukemia but also further elucidates the 
downstream events modulated by NS in T-ALL 
cells.  
Firstly, we showed the effects of RNA 
interference (RNAi) in reducing NS gene 
expression in a different human T-ALL cell lines. 
Our results also showed that 24 hoursafter NS 
silencing, a significant growth inhibition is 
observed in both Molt-4 and Jurkat cells followed 
with more inhibitory effects at longer intervals 
(48 hours and 72 hours). Similar results obtained 
on different leukemia cells where rate of cell 
proliferation decreased 24 hours after NS 
inhibition [2,20]. In addition, NS depletion 
reduced proliferation of many different cancerous 
cell lines such as PC-3, 5637 and Hela cells 
[11,16,18]. This may be due to major regulatory 
role of NS in promoting cell-cycle and self-
renewal of stem and cancer cells [6].Therefore, 
we also examined the in vitro effects of NS 
depletion on clonogenic growth. Upon serial 
replating (without further silencing of NS), 
secondary colony formation was significantly 
inhibited by NS-siRNA, suggesting critical roles 
of NS in controlling self-renewal of T-ALL cells. 
These findings suggest that NS gene silencing by 
NS-siRNA induced reduction in the rate of cell 
proliferationand represents a major regulatory role 
for NS in promoting cell cycle and self-renewal of 
stem and cancer cells.  
Apoptosis induction is a typical event that is 
observed following NS depletion. It is noticeable 
that Jurkatcells were more sensitive at shorter 
times of post-transfection (48 hours) than Molt-4 
cells. Molt-4 cells were also susceptible to 
apoptosis, albeit with different kinetic; apoptosis 
and concurrent decrease in viability occurred only 
after 48 hours of NS depletion (Figure 3). Indeed, 
Molt-4 cells with functional p53 protein were 
somewhat resistant to apoptosis than Jurkat cells 
(which has a defective p53 pathway) and a 
delayed apoptosis after 48 hours and 72 hours of 
NS-transfection was observed in Molt-4 cells. 
Both early and late apoptosis induction after NS 
depletion havealso been reported in several 
studies. For example, in PC-3 prostate and HL-60 
cells, NS depletion resulted in growth inhibition 
and rapid apoptotic response [11,20]. In K562 
leukemia cells, however, a delayed apoptotic 
response has been observed [12]. 
The severe effects of NS silencing on the viability 
and apoptosis of p53-null Jurkatcells (Figures 2 
and 3) is ratherunexpected, because it has been 
previously demonstrated that apoptosis induction 
after NS depletion is mediated through p53. A 
possible explanation may be the level of NS 
 




knocking-down in both cells; based on Figure 1, 
NS-siRNA more potently depleted NS in Jurkat 
cells than Molt-4 cells. Another possible 
explanation for this apparent discrepancy may be 
the differences in phenotype and differentiation 
status of both cells of NS knocking-down in both 
types of cells. Also, it may be concluded that NS 
effects are mediated via p53-independent 
pathways, as previously reported [2, 10, 12]. 
 
CONCLUSION  
     In conclusion, NSis expressed at high levels in 
T-ALL cells. Following NS-depletion, the Molt-4 
and the Jurkat cells exhibited inhibition of self-
renewal and proliferation andshowed apoptotic 
response. These results highlight the importance 
of this stem cell-related gene as a therapeutic 
target for leukemia. 
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